CompletedPhase 3NCT01928537
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Studying Chronic myelomonocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Traws Pharma, Inc.
- Principal Investigator
- Steven M. Fruchtman, MDTraws Pharma, Inc.
- Intervention
- rigosertib sodium(drug)
- Enrollment
- 67 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2017
Study locations (30)
- Stanford University Cancer Center, Stanford, California, United States
- Rush University Medical Center, Chicago, Illinois, United States
- University of Chicago Medicine, Chicago, Illinois, United States
- University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States
- Greenbaum Cancer Center University of Maryland, Baltimore, Maryland, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Mount Sinai Medical Center, New York, New York, United States
- Columbia University Medical Center, New York, New York, United States
- New York Presbyterian Hospital-Weill Cornell Medical College, New York, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- University of Texas Southwestern Medical Center-Parkland Hospital, Dallas, Texas, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Royal Adelaide Hospital, Adelaide, South Australia, Australia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01928537 on ClinicalTrials.govOther trials for Chronic myelomonocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07071155Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic LeukemiaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGNCT07512882Cohort of Patients With Chronic Myelomonocytic LeukemiaGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGPHASE2NCT06815003Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity ConditioningCity of Hope Medical Center
- RECRUITINGPHASE2NCT06597734A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative NeoplasmM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT06543381Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell TransplantCity of Hope Medical Center
- RECRUITINGPHASE3NCT06647862IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- RECRUITINGPHASE1, PHASE2NCT06159491Pacritinib in CMMLDouglas Tremblay
- RECRUITINGPHASE1NCT06218628Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionFox Chase Cancer Center